Home›Trial›NCT06585462
🔬NCT06585462Phase 1RECRUITING

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Study Summary

The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.

Conditions
Cardiometabolic Disease
Interventions / Drugs
AMG 513PlaceboAMG 513Placebo
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment80 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.157802+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.